Rhythm Biosciences’ ColoSTAT Gains Clinical Traction in Commercial Rollout
ColoSTAT showing early signs of clinical traction in commercial rollout with 4Cyte Pathology
Rhythm Biosciences has reported early indicators of clinical adoption for its ColoSTAT blood test, demonstrating real-world demand through commercial deployment with 4Cyte Pathology. The blood-based colorectal cancer triage tool is expanding into underserved patient groups, including elderly, mobility-limited, geographically remote, and home-based patients, representing a shift from clinical validation to commercial utilisation.
This represents early commercial validation beyond controlled trial settings. ColoSTAT is being used as a frontline triage tool for symptomatic patients, addressing barriers in traditional diagnostic pathways where invasive procedures and logistical challenges limit access.
For investors, this signals the bridge from research and development to revenue generation. Early commercial traction validates the business model and demonstrates repeatable demand in real-world healthcare settings.
When big ASX news breaks, our subscribers know first
What is ColoSTAT and why does blood-based CRC triage matter?
ColoSTAT is a blood-based test that measures five specific protein biomarkers to indicate the likelihood of colorectal cancer in symptomatic patients. It is designed to support clinicians in making triage decisions, offering an alternative to invasive colonoscopies and stool-based tests, both of which face compliance and access barriers.
Colorectal cancer is the second leading cause of cancer deaths globally. Early detection significantly improves survival rates, but traditional diagnostic pathways present challenges.
Colonoscopies are resource-intensive and invasive, requiring procedural preparation and hospital infrastructure. Stool-based tests face patient compliance issues, particularly among elderly and mobility-limited populations.
Blood-based diagnostics address these barriers by offering a simple, non-invasive option that can be integrated into existing pathology infrastructure. If ColoSTAT can capture even a fraction of the symptomatic patient triage market, the commercial opportunity is substantial.
Real-world case studies demonstrate practical applicability
Rhythm has outlined two case studies that demonstrate ColoSTAT’s utility in complex patient scenarios. These examples provide initial evidence of the test’s practical applicability across underserved patient groups.
| Case Study | ColoSTAT Solution |
|---|---|
| Elderly patient (80s), Far North NSW — symptomatic, remote from pathology infrastructure | Home blood collection enabled diagnostic triage without travel or invasive procedures |
| Mobility-limited patient, Sunshine Coast QLD — significant mobility limitations, complex health profile | Local collection centre testing avoided hospital-based diagnostics and procedural preparation |
These cases validate scalable collection pathways that integrate into existing healthcare infrastructure. Home-based and community pathology centre testing does not require new facilities, lowering the barrier to commercial scale and accelerating the path to revenue.
Scalable model positions ColoSTAT for broader adoption
The company is validating two collection pathways: home-based blood collection and community pathology centres. This integration into existing pathology infrastructure positions ColoSTAT for broader adoption without requiring significant capital investment in new channels.
Rhythm identifies three key benefits of the ColoSTAT model:
- Improved patient access and adoption
- Earlier triage decisions
- More efficient use of colonoscopy resources
By reducing reliance on invasive procedures and stool-based testing, ColoSTAT addresses key barriers in the current diagnostic pathway. For investors, this scalability is critical. Integration into existing pathology infrastructure accelerates the path to revenue and reduces the risk associated with building new distribution channels.
CEO commentary on commercial momentum
CEO & Managing Director Dr David Atkins
“We are beginning to see early signs of how ColoSTAT® is being adopted in real-world clinical settings, particularly in patient groups where traditional diagnostic pathways present challenges. A key advantage of ColoSTAT® is its ability to reduce reliance on invasive procedures and stool-based testing, supporting more accessible diagnostic pathways for patients.”
Dr Atkins framed the early commercial signals as evidence of repeatable clinical demand. The company is focused on building further real-world evidence to support broader clinical adoption, indicating active commercial expansion.
The next major ASX story will hit our subscribers first
Upcoming investor webinar and next steps
Rhythm has scheduled a quarterly investor webinar for Wednesday, 13 May 2026 at 10:00am AEST. CEO Dr David Atkins and members of the team will provide an update on recent progress, including developments from the commercial programme and broader market insights.
Shareholders can register in advance at this link and submit questions via investors@rhythmbio.com. Management engagement via investor webinars signals commitment to shareholder communication. The focus on building further real-world evidence indicates the company is in active commercial expansion mode, moving beyond clinical validation toward revenue generation.
Want the Next Healthcare Breakthrough in Your Inbox?
Join 20,000+ investors getting FREE breaking ASX healthcare news delivered within minutes of release, complete with in-depth analysis. Click the “Free Alerts” button at Big News Blast to receive real-time alerts the moment market-moving announcements hit the ASX.